Nombre del producto:9-methyl-9-azabicyclo[3.3.1]nonan-3-one

IUPAC Name:9-methyl-9-azabicyclo[3.3.1]nonan-3-one

CAS:552-70-5
Fórmula molecular:C9H15NO
Pureza:98%
Número de catálogo:CM108204
Peso molecular:153.23

Unidad de embalaje Stock disponible Precio($) Cantidad
CM108204-5g in stock ľŤ
CM108204-10g in stock ƚŤŌ
CM108204-25g in stock ŌľǸ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :552-70-5
Fórmula molecular:C9H15NO
Punto de fusión:-
Código de sonrisas:O=C1CC(N2C)CCCC2C1
Densidad:
Número de catálogo:CM108204
Peso molecular:153.23
Punto de ebullición:246.7°C at 760 mmHg
Nº Mdl:MFCD00078161
Almacenamiento:Store at 2-8°C.

Category Infos

Piperidines
Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
Piperidine,Piperidine Price
if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.
Bridged Compounds
Bridged ring compound refers to any two rings in the compound, which share two non-directly connected carbon atoms, and are classified into bicyclic hydrocarbons, tricyclic hydrocarbons, tetracyclic hydrocarbons, etc. Carbon atoms used in two or more rings are bridgehead carbon atoms, and the bond connecting the bridgehead carbon atoms is called a bridge. Bridged ring compounds are a class of organic compounds that are widely present in nature and usually have important physiological activities, such as the famous anticancer drug paclitaxel and antimalarial drug artemisinin.
bridged compounds,bridged bicyclic compounds
Buy low price, high quality bridged compounds and bridged bicyclic compounds,choose our products,Chemenu is the leading factory & company. Warmly welcome new and old customers to visit and patronize!

Column Infos

Sunobinop
Sunobinop is an investigational, novel and potential first-in-class oral compound discovered by Imbrium Therapeutics and that is currently in clinical development. Sunobinop is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions, including bladder function.
As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.